Industry Research Reports
Home > Reports > Pharma & Healthcare > Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Global Varicella Vaccine Industry Research Report, Growth Trends and Competitive Analysis 2024-2030
Industry: Pharma & Healthcare
Published Date: 2024-04-17
Pages: 140 Pages
Report ld: 2700609
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Varicella Vaccine Market Size(US$)
CAGR 2024-2030
7.8%
Market Size,2030
USD 7,104.7
Million
Market Snapshot
Market Size in 2024 (Value)
US$ 4,527.3 million
Market Forecast in 2030(Value)
US$ 7,104.7 million
CAGR
7.8%
Years Considered
2019-2030
Base Year
2024
Forecast Period
2024-2030
Source: Secondary research, interviews with experts, and QYResearch analysis
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
The global Varicella Vaccine market size was US$ 4174 million in 2023 and is forecast to a readjusted size of US$ 7104.7 million by 2030 with a CAGR of 7.8% during the forecast period 2024-2030.
Global Varicella Vaccine key players include Merck, Shanghai Institute, Changsheng, Keygen, GSK, etc.
Asia is the largest market, with a share over 35%, followed by US and Europe, both have a share over 55%.
In terms of product, Freeze-Dried Powder is the largest segment, with a share over 50%. And in terms of application, the largest application is Kids Injection, followed by Adults Injection, etc.
In terms of sales (consumption) side, this report focuses on the sales of Varicella Vaccine by regions (Countries), company, by type and by type. from 2019 to 2024 and forecast to 2030.
The global Varicella Vaccine market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Varicella Vaccine market. These figures have been provided in terms of both revenue and sales for the period 2019-2030. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.
MARKET SEGMENTATION
By Company
- Merck
- GSK
- Shanghai Institute
- BCHT
- Changsheng
- Keygen
- Green Cross
- Biken
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Injection
- Freeze-Dried Powder
Segment by Application
- Kids Injection
- Adults Injection
CHAPTER OUTLINE
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Varicella Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Varicella Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7: Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8: China by company, by type and by application, sales, and revenue for each segment.
Chapter 9: APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Varicella Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Report Overview
1.1 Varicella Vaccine Definition
1.2 Market by Type
1.2.1 Global Varicella Vaccine Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Injection
1.2.3 Freeze-Dried Powder
1.3 Market Segment by Application
1.3.1 Global Varicella Vaccine Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Kids Injection
1.3.3 Adults Injection
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Varicella Vaccine Sales
2.1 Global Varicella Vaccine Revenue Estimates and Forecasts 2019-2030
2.2 Global Varicella Vaccine Revenue by Region: 2019 VS 2023 VS 2030
2.3 Global Varicella Vaccine Revenue by Region
2.3.1 Global Varicella Vaccine Revenue by Region (2019-2024)
2.3.2 Global Varicella Vaccine Revenue by Region (2025-2030)
2.4 Global Varicella Vaccine Sales Quantity Estimates and Forecasts 2019-2030
2.5 Global Varicella Vaccine Sales Quantity by Region: 2019 VS 2023 VS 2030
2.6 Global Varicella Vaccine Sales Quantity by Region
2.6.1 Global Varicella Vaccine Sales Quantity by Region (2019-2024)
2.6.2 Global Varicella Vaccine Sales Quantity by Region (2025-2030)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Varicella Vaccine Sales Quantity by Manufacturers
3.1.1 Global Varicella Vaccine Sales Quantity by Manufacturers (2019-2024)
3.1.2 Global Varicella Vaccine Sales Quantity Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Companies by Varicella Vaccine Sales in 2023
3.2 Global Varicella Vaccine Revenue by Manufacturers
3.2.1 Global Varicella Vaccine Revenue by Manufacturers (2019-2024)
3.2.2 Global Varicella Vaccine Revenue Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Varicella Vaccine Revenue in 2023
3.3 Global Varicella Vaccine Sales Price by Manufacturers
3.4 Global Key Players of Varicella Vaccine, Industry Ranking, 2022 VS 2023
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Varicella Vaccine, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Varicella Vaccine, Product Offered and Application
3.8 Global Key Manufacturers of Varicella Vaccine, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Varicella Vaccine Sales Quantity by Type
4.1.1 Global Varicella Vaccine Historical Sales Quantity by Type (2019-2024)
4.1.2 Global Varicella Vaccine Forecasted Sales Quantity by Type (2025-2030)
4.1.3 Global Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
4.2 Global Varicella Vaccine Revenue by Type
4.2.1 Global Varicella Vaccine Historical Revenue by Type (2019-2024)
4.2.2 Global Varicella Vaccine Forecasted Revenue by Type (2025-2030)
4.2.3 Global Varicella Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Varicella Vaccine Price by Type
4.3.1 Global Varicella Vaccine Price by Type (2019-2024)
4.3.2 Global Varicella Vaccine Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Varicella Vaccine Sales Quantity by Application
5.1.1 Global Varicella Vaccine Historical Sales Quantity by Application (2019-2024)
5.1.2 Global Varicella Vaccine Forecasted Sales Quantity by Application (2025-2030)
5.1.3 Global Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
5.2 Global Varicella Vaccine Revenue by Application
5.2.1 Global Varicella Vaccine Historical Revenue by Application (2019-2024)
5.2.2 Global Varicella Vaccine Forecasted Revenue by Application (2025-2030)
5.2.3 Global Varicella Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Varicella Vaccine Price by Application
5.3.1 Global Varicella Vaccine Price by Application (2019-2024)
5.3.2 Global Varicella Vaccine Price Forecast by Application (2025-2030)
6 North America
6.1 North America Varicella Vaccine Sales by Company
6.1.1 North America Varicella Vaccine Revenue by Company (2019-2024)
6.1.2 North America Varicella Vaccine Sales Quantity by Company (2019-2024)
6.2 North America Varicella Vaccine Market Size by Type
6.2.1 North America Varicella Vaccine Sales Quantity by Type (2019-2030)
6.2.2 North America Varicella Vaccine Revenue by Type (2019-2030)
6.3 North America Varicella Vaccine Market Size by Application
6.3.1 North America Varicella Vaccine Sales Quantity by Application (2019-2030)
6.3.2 North America Varicella Vaccine Revenue by Application (2019-2030)
6.4 North America Varicella Vaccine Market Size by Country
6.4.1 North America Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030
6.4.2 North America Varicella Vaccine Revenue by Country (2019-2030)
6.4.3 North America Varicella Vaccine Sales Quantity by Country (2019-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Varicella Vaccine Sales by Company
7.1.1 Europe Varicella Vaccine Sales Quantity by Company (2019-2024)
7.1.2 Europe Varicella Vaccine Revenue by Company (2019-2024)
7.2 Europe Varicella Vaccine Market Size by Type
7.2.1 Europe Varicella Vaccine Sales Quantity by Type (2019-2030)
7.2.2 Europe Varicella Vaccine Revenue by Type (2019-2030)
7.3 Europe Varicella Vaccine Market Size by Application
7.3.1 Europe Varicella Vaccine Sales Quantity by Application (2019-2030)
7.3.2 Europe Varicella Vaccine Revenue by Application (2019-2030)
7.4 Europe Varicella Vaccine Market Size by Country
7.4.1 Europe Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Varicella Vaccine Revenue by Country (2019-2030)
7.4.3 Europe Varicella Vaccine Sales Quantity by Country (2019-2030)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Varicella Vaccine Sales by Company
8.1.1 China Varicella Vaccine Sales Quantity by Company (2019-2024)
8.1.2 China Varicella Vaccine Revenue by Company (2019-2024)
8.2 China Varicella Vaccine Market Size by Type
8.2.1 China Varicella Vaccine Sales Quantity by Type (2019-2030)
8.2.2 China Varicella Vaccine Revenue by Type (2019-2030)
8.3 China Varicella Vaccine Market Size by Application
8.3.1 China Varicella Vaccine Sales Quantity by Application (2019-2030)
8.3.2 China Varicella Vaccine Revenue by Application (2019-2030)
9 APAC (excluding China)
9.1 APAC Varicella Vaccine Sales by Company
9.1.1 APAC Varicella Vaccine Sales Quantity by Company (2019-2024)
9.1.2 APAC Varicella Vaccine Revenue by Company (2019-2024)
9.2 APAC Varicella Vaccine Market Size by Type
9.2.1 APAC Varicella Vaccine Sales Quantity by Type (2019-2030)
9.2.2 APAC Varicella Vaccine Revenue by Type (2019-2030)
9.3 APAC Varicella Vaccine Market Size by Application
9.3.1 APAC Varicella Vaccine Sales Quantity by Application (2019-2030)
9.3.2 APAC Varicella Vaccine Revenue by Application (2019-2030)
9.4 APAC Varicella Vaccine Market Size by Region
9.4.1 APAC Varicella Vaccine Revenue by Region: 2019 VS 2023 VS 2030
9.4.2 APAC Varicella Vaccine Revenue by Region (2019-2030)
9.4.3 APAC Varicella Vaccine Sales Quantity by Region (2019-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Varicella Vaccine Sales by Company
10.1.1 Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Company (2019-2024)
10.1.2 Middle East, Africa and Latin America Varicella Vaccine Revenue by Company (2019-2024)
10.2 Middle East, Africa and Latin America Varicella Vaccine Market Size by Type
10.2.1 Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Type (2019-2030)
10.2.2 Middle East, Africa and Latin America Varicella Vaccine Revenue by Type (2019-2030)
10.3 Middle East, Africa and Latin America Varicella Vaccine Market Size by Application
10.3.1 Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Application (2019-2030)
10.3.2 Middle East, Africa and Latin America Varicella Vaccine Revenue by Application (2019-2030)
10.4 Middle East, Africa and Latin America Varicella Vaccine Market Size by Country
10.4.1 Middle East, Africa and Latin America Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa and Latin America Varicella Vaccine Revenue by Country (2019-2030)
10.4.3 Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Country (2019-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.1.4 Merck Varicella Vaccine Products and Services
11.1.5 Merck Varicella Vaccine SWOT Analysis
11.1.6 Merck Recent Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Overview
11.2.3 GSK Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.2.4 GSK Varicella Vaccine Products and Services
11.2.5 GSK Varicella Vaccine SWOT Analysis
11.2.6 GSK Recent Developments
11.3 Shanghai Institute
11.3.1 Shanghai Institute Company Information
11.3.2 Shanghai Institute Overview
11.3.3 Shanghai Institute Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.3.4 Shanghai Institute Varicella Vaccine Products and Services
11.3.5 Shanghai Institute Varicella Vaccine SWOT Analysis
11.3.6 Shanghai Institute Recent Developments
11.4 BCHT
11.4.1 BCHT Company Information
11.4.2 BCHT Overview
11.4.3 BCHT Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.4.4 BCHT Varicella Vaccine Products and Services
11.4.5 BCHT Varicella Vaccine SWOT Analysis
11.4.6 BCHT Recent Developments
11.5 Changsheng
11.5.1 Changsheng Company Information
11.5.2 Changsheng Overview
11.5.3 Changsheng Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.5.4 Changsheng Varicella Vaccine Products and Services
11.5.5 Changsheng Varicella Vaccine SWOT Analysis
11.5.6 Changsheng Recent Developments
11.6 Keygen
11.6.1 Keygen Company Information
11.6.2 Keygen Overview
11.6.3 Keygen Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.6.4 Keygen Varicella Vaccine Products and Services
11.6.5 Keygen Varicella Vaccine SWOT Analysis
11.6.6 Keygen Recent Developments
11.7 Green Cross
11.7.1 Green Cross Company Information
11.7.2 Green Cross Overview
11.7.3 Green Cross Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.7.4 Green Cross Varicella Vaccine Products and Services
11.7.5 Green Cross Varicella Vaccine SWOT Analysis
11.7.6 Green Cross Recent Developments
11.8 Biken
11.8.1 Biken Company Information
11.8.2 Biken Overview
11.8.3 Biken Varicella Vaccine Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2019-2024)
11.8.4 Biken Varicella Vaccine Products and Services
11.8.5 Biken Varicella Vaccine SWOT Analysis
11.8.6 Biken Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Varicella Vaccine Value Chain Analysis
12.2 Varicella Vaccine Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Varicella Vaccine Production Mode & Process
12.4 Varicella Vaccine Sales and Marketing
12.4.1 Varicella Vaccine Sales Channels
12.4.2 Varicella Vaccine Distributors
12.5 Varicella Vaccine Customers
13 Market Dynamics
13.1 Varicella Vaccine Industry Trends
13.2 Varicella Vaccine Market Drivers
13.3 Varicella Vaccine Market Challenges
13.4 Varicella Vaccine Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
TABLE OF FIGURES
List of Tables
Table 1. Global Varicella Vaccine Market Size Growth Rate (CAGR) by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Injection
Table 3. Major Manufacturers of Freeze-Dried Powder
Table 4. Global Varicella Vaccine Market Size Growth Rate (CAGR) by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 5. Global Varicella Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 6. Global Varicella Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 7. Global Varicella Vaccine Revenue Market Share by Region (2019-2024)
Table 8. Global Varicella Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 9. Global Varicella Vaccine Revenue Market Share by Region (2025-2030)
Table 10. Global Varicella Vaccine Sales Quantity by Region: 2019 VS 2023 VS 2030 (M Doses)
Table 11. Global Varicella Vaccine Sales by Region (2019-2024) & (M Doses)
Table 12. Global Varicella Vaccine Sales Market Share by Region (2019-2024)
Table 13. Global Varicella Vaccine Sales by Region (2025-2030) & (M Doses)
Table 14. Global Varicella Vaccine Sales Market Share by Region (2025-2030)
Table 15. Global Varicella Vaccine Sales Quantity by Manufacturers (2019-2024) & (M Doses)
Table 16. Global Varicella Vaccine Sales Quantity Share by Manufacturers (2019-2024)
Table 17. Global Varicella Vaccine Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 18. Global Varicella Vaccine Revenue Share by Manufacturers (2019-2024)
Table 19. Global Varicella Vaccine Price by Manufacturers 2019-2024 (USD/Dose)
Table 20. Global Key Players of Varicella Vaccine, Industry Ranking, 2022 VS 2023
Table 21. Global Varicella Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Varicella Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Varicella Vaccine as of 2023)
Table 23. Global Key Manufacturers of Varicella Vaccine, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Varicella Vaccine, Product Offered and Application
Table 25. Global Key Manufacturers of Varicella Vaccine, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 28. Global Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 29. Global Varicella Vaccine Sales Quantity Share by Type (2019-2024)
Table 30. Global Varicella Vaccine Sales Quantity Share by Type (2025-2030)
Table 31. Global Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 32. Global Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 33. Global Varicella Vaccine Revenue Share by Type (2019-2024)
Table 34. Global Varicella Vaccine Revenue Share by Type (2025-2030)
Table 35. Varicella Vaccine Price by Type (2019-2024) & (USD/Dose)
Table 36. Global Varicella Vaccine Price Forecast by Type (2025-2030) & (USD/Dose)
Table 37. Global Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 38. Global Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 39. Global Varicella Vaccine Sales Quantity Share by Application (2019-2024)
Table 40. Global Varicella Vaccine Sales Quantity Share by Application (2025-2030)
Table 41. Global Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 42. Global Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 43. Global Varicella Vaccine Revenue Share by Application (2019-2024)
Table 44. Global Varicella Vaccine Revenue Share by Application (2025-2030)
Table 45. Varicella Vaccine Price by Application (2019-2024) & (USD/Dose)
Table 46. Global Varicella Vaccine Price Forecast by Application (2025-2030) & (USD/Dose)
Table 47. North America Varicella Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 48. North America Varicella Vaccine Sales Quantity by Company (2019-2024) & (M Doses)
Table 49. North America Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 50. North America Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 51. North America Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 52. North America Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 53. North America Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 54. North America Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 55. North America Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 56. North America Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 57. North America Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 58. North America Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 59. North America Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 60. North America Varicella Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
Table 61. North America Varicella Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
Table 62. Europe Varicella Vaccine Sales Quantity by Company (2019-2024) & (M Doses)
Table 63. Europe Varicella Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 64. Europe Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 65. Europe Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 66. Europe Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 67. Europe Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 68. Europe Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 69. Europe Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 70. Europe Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 71. Europe Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 72. Europe Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 73. Europe Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 74. Europe Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 75. Europe Varicella Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
Table 76. Europe Varicella Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
Table 77. China Varicella Vaccine Sales Quantity by Company (2019-2024) & (M Doses)
Table 78. China Varicella Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 79. China Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 80. China Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 81. China Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 82. China Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 83. China Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 84. China Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 85. China Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 86. China Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 87. APAC Varicella Vaccine Sales Quantity by Company (2019-2024) & (M Doses)
Table 88. APAC Varicella Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 89. APAC Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 90. APAC Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 91. APAC Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 92. APAC Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 93. APAC Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 94. APAC Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 95. APAC Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 96. APAC Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 97. APAC Varicella Vaccine Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 98. APAC Varicella Vaccine Revenue by Region (2019-2024) & (US$ Million)
Table 99. APAC Varicella Vaccine Revenue by Region (2025-2030) & (US$ Million)
Table 100. APAC Varicella Vaccine Sales Quantity by Region (2019-2024) & (M Doses)
Table 101. APAC Varicella Vaccine Sales Quantity by Region (2025-2030) & (M Doses)
Table 102. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Company (2019-2024) & (M Doses)
Table 103. Middle East, Africa and Latin America Varicella Vaccine Revenue by Company (2019-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Type (2019-2024) & (M Doses)
Table 105. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Type (2025-2030) & (M Doses)
Table 106. Middle East, Africa and Latin America Varicella Vaccine Revenue by Type (2019-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Varicella Vaccine Revenue by Type (2025-2030) & (US$ Million)
Table 108. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Application (2019-2024) & (M Doses)
Table 109. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Application (2025-2030) & (M Doses)
Table 110. Middle East, Africa and Latin America Varicella Vaccine Revenue by Application (2019-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Varicella Vaccine Revenue by Application (2025-2030) & (US$ Million)
Table 112. Middle East, Africa and Latin America Varicella Vaccine Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 113. Middle East, Africa and Latin America Varicella Vaccine Revenue by Country (2019-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Varicella Vaccine Revenue by Country (2025-2030) & (US$ Million)
Table 115. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Country (2019-2024) & (M Doses)
Table 116. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity by Country (2025-2030) & (M Doses)
Table 117. Merck Company Information
Table 118. Merck Description and Overview
Table 119. Merck Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 120. Merck Varicella Vaccine Product and Services
Table 121. Merck Varicella Vaccine SWOT Analysis
Table 122. Merck Recent Developments
Table 123. GSK Company Information
Table 124. GSK Description and Overview
Table 125. GSK Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 126. GSK Varicella Vaccine Product and Services
Table 127. GSK Varicella Vaccine SWOT Analysis
Table 128. GSK Recent Developments
Table 129. Shanghai Institute Company Information
Table 130. Shanghai Institute Description and Overview
Table 131. Shanghai Institute Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 132. Shanghai Institute Varicella Vaccine Product and Services
Table 133. Shanghai Institute Varicella Vaccine SWOT Analysis
Table 134. Shanghai Institute Recent Developments
Table 135. BCHT Company Information
Table 136. BCHT Description and Overview
Table 137. BCHT Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 138. BCHT Varicella Vaccine Product and Services
Table 139. BCHT Varicella Vaccine SWOT Analysis
Table 140. BCHT Recent Developments
Table 141. Changsheng Company Information
Table 142. Changsheng Description and Overview
Table 143. Changsheng Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 144. Changsheng Varicella Vaccine Product and Services
Table 145. Changsheng Varicella Vaccine SWOT Analysis
Table 146. Changsheng Recent Developments
Table 147. Keygen Company Information
Table 148. Keygen Description and Overview
Table 149. Keygen Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 150. Keygen Varicella Vaccine Product and Services
Table 151. Keygen Varicella Vaccine SWOT Analysis
Table 152. Keygen Recent Developments
Table 153. Green Cross Company Information
Table 154. Green Cross Description and Overview
Table 155. Green Cross Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 156. Green Cross Varicella Vaccine Product and Services
Table 157. Green Cross Varicella Vaccine SWOT Analysis
Table 158. Green Cross Recent Developments
Table 159. Biken Company Information
Table 160. Biken Description and Overview
Table 161. Biken Varicella Vaccine Sales Quantity (M Doses), Revenue (US$ Million), Average Selling Price (ASP) (USD/Dose) and Gross Margin (2019-2024)
Table 162. Biken Varicella Vaccine Product and Services
Table 163. Biken Varicella Vaccine SWOT Analysis
Table 164. Biken Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Varicella Vaccine Distributors List
Table 168. Varicella Vaccine Customers List
Table 169. Varicella Vaccine Market Trends
Table 170. Varicella Vaccine Market Drivers
Table 171. Varicella Vaccine Market Challenges
Table 172. Varicella Vaccine Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Varicella Vaccine Product Picture
Figure 2. Global Varicella Vaccine Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Varicella Vaccine Market Share by Type in 2023 & 2030
Figure 4. Injection Product Picture
Figure 5. Freeze-Dried Powder Product Picture
Figure 6. Global Varicella Vaccine Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 7. Global Varicella Vaccine Market Share by Application in 2023 & 2030
Figure 8. Kids Injection
Figure 9. Adults Injection
Figure 10. Varicella Vaccine Report Years Considered
Figure 11. Global Varicella Vaccine Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Varicella Vaccine Revenue 2019-2030 (US$ Million)
Figure 13. Global Varicella Vaccine Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 14. Global Varicella Vaccine Sales Quantity 2019-2030 (M Doses)
Figure 15. Global Varicella Vaccine Sales Quantity Market Share by Region (2019-2024)
Figure 16. Global Varicella Vaccine Sales Quantity Market Share by Region (2025-2030)
Figure 17. North America Varicella Vaccine Sales Quantity YoY (2019-2030) & (M Doses)
Figure 18. North America Varicella Vaccine Revenue YoY (2019-2030) & (US$ Million)
Figure 19. Europe Varicella Vaccine Sales Quantity YoY (2019-2030) & (M Doses)
Figure 20. Europe Varicella Vaccine Revenue YoY (2019-2030) & (US$ Million)
Figure 21. China Varicella Vaccine Sales Quantity YoY (2019-2030) & (M Doses)
Figure 22. China Varicella Vaccine Revenue YoY (2019-2030) & (US$ Million)
Figure 23. APAC Varicella Vaccine Sales Quantity YoY (2019-2030) & (M Doses)
Figure 24. APAC Varicella Vaccine Revenue YoY (2019-2030) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity YoY (2019-2030) & (M Doses)
Figure 26. Middle East, Africa and Latin America Varicella Vaccine Revenue YoY (2019-2030) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Varicella Vaccine Sales Quantity in 2023
Figure 28. The Top 10 and Top 5 Players Market Share by Varicella Vaccine Revenue in 2023
Figure 29. Varicella Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 30. Global Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 31. Global Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 32. Global Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 34. North America Varicella Vaccine Revenue Market Share by Company in 2023
Figure 35. North America Varicella Vaccine Sales Quantity Market Share by Company in 2023
Figure 36. North America Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 37. North America Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 38. North America Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 39. North America Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 40. North America Varicella Vaccine Revenue Share by Country (2019-2030)
Figure 41. North America Varicella Vaccine Sales Quantity Share by Country (2019-2030)
Figure 42. U.S. Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 43. Canada Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 44. Europe Varicella Vaccine Sales Quantity Market Share by Company in 2023
Figure 45. Europe Varicella Vaccine Revenue Market Share by Company in 2023
Figure 46. Europe Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 47. Europe Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 48. Europe Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 49. Europe Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 50. Europe Varicella Vaccine Revenue Share by Country (2019-2030)
Figure 51. Europe Varicella Vaccine Sales Quantity Share by Country (2019-2030)
Figure 52. Germany Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 53. France Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 54. U.K. Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 55. Italy Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 56. Russia Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 57. China Varicella Vaccine Sales Quantity Market Share by Company in 2023
Figure 58. China Varicella Vaccine Revenue Market Share by Company in 2023
Figure 59. China Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 60. China Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 61. China Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 62. China Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 63. APAC Varicella Vaccine Sales Quantity Market Share by Company in 2023
Figure 64. APAC Varicella Vaccine Revenue Market Share by Company in 2023
Figure 65. APAC Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 66. APAC Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 67. APAC Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 68. APAC Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 69. APAC Varicella Vaccine Revenue Share by Region (2019-2030)
Figure 70. APAC Varicella Vaccine Sales Quantity Share by Region (2019-2030)
Figure 71. Japan Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 72. South Korea Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 73. China Taiwan Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 74. Southeast Asia Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 75. India Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity Market Share by Company in 2023
Figure 77. Middle East, Africa and Latin America Varicella Vaccine Revenue Market Share by Company in 2023
Figure 78. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity Market Share by Type (2019-2030)
Figure 79. Middle East, Africa and Latin America Varicella Vaccine Revenue Market Share by Type (2019-2030)
Figure 80. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity Market Share by Application (2019-2030)
Figure 81. Middle East, Africa and Latin America Varicella Vaccine Revenue Market Share by Application (2019-2030)
Figure 82. Middle East, Africa and Latin America Varicella Vaccine Sales Quantity Share by Country (2019-2030)
Figure 83. Middle East, Africa and Latin America Varicella Vaccine Revenue Share by Country (2019-2030)
Figure 84. Brazil Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 85. Mexico Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 86. Turkey Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 87. Israel Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 88. GCC Countries Varicella Vaccine Revenue (2019-2030) & (US$ Million)
Figure 89. Varicella Vaccine Value Chain
Figure 90. Varicella Vaccine Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
Which region is expected to have the highest market share?
For each regional market, the report conducted in-depth comparative analysis from multiple dimensions such as market size, 7.8% compound annual growth rate, market demand, industrial structure, policy environment, and the layout of major enterprises. It systematically summarized the market characteristics and competitive environment of different regions. At the same time, it also focused on analyzing the demand structure, market growth drivers, and investment environment of each region, providing valuable references for enterprises to identify key regional markets, formulate global market layouts and sales strategies.
What is the annual compound growth rate of the global Varicella Vaccine market size from 2024 to 2030?
Which companies rank high in the global Varicella Vaccine market?
What was the global market size of Varicella Vaccine in 2030?
What was the global market size of Varicella Vaccine in 2024?
Related Reports
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published Date: 2026-01-04
Pages: 79
USD 4250.00
(Single User License)
Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 114
USD 2900.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published Date: 2026-01-04
Pages: 96
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published Date: 2025-09-11
Pages: 149
USD 4900.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-28
Pages: 135
USD 5900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-03-19
Pages: 77
USD 4250.00
(Single User License)
Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published Date: 2025-01-16
Pages: 95
USD 3950.00
(Single User License)
Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published Date: 2025-01-16
Pages: 80
USD 2900.00
(Single User License)
Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-16
Pages: 130
USD 5900.00
(Single User License)
Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published Date: 2024-04-07
Pages: 87
USD 4900.00
(Single User License)
Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global Varicella Vaccine market size was US$ 5185 million in 2025 and is forecast to reach a readjusted size of US$ 8708 million by 2032 with a CAGR of 7.8% during the forecast period 2026-2032.
Published: 2026-01-04
Pages: 79
USD 4250.00 (Single User License)Global Varicella Vaccine Market Research Report 2026
The global Varicella Vaccine market was valued at US$ 5185 million in 2025 and is anticipated to reach US$ 8708 million by 2032, at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 114
USD 2900.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Varicella Vaccine was estimated to be worth US$ 5185 million in 2025 and is projected to reach US$ 8708 million, growing at a CAGR of 7.8% from 2026 to 2032.
Published: 2026-01-04
Pages: 96
USD 3950.00 (Single User License)Global Varicella Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
The global Varicella Vaccine market is projected to grow from US$ 4845 million in 2024 to US$ 8137 million by 2031, at a CAGR of 7.8% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
Published: 2025-09-11
Pages: 149
USD 4900.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
In 2024, the global market size of Varicella Vaccine was estimated to be worth US$ 4845 million and is forecast to reach approximately US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-28
Pages: 135
USD 5900.00 (Single User License)Global Varicella Vaccine Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Varicella Vaccine market size was US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-03-19
Pages: 77
USD 4250.00 (Single User License)Varicella Vaccine- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Varicella Vaccine was estimated to be worth US$ 4845 million in 2024 and is forecast to a readjusted size of US$ 8137 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.
Published: 2025-01-16
Pages: 95
USD 3950.00 (Single User License)Global Varicella Vaccine Market Research Report 2025
The global market for Varicella Vaccine was valued at US$ 4845 million in the year 2024 and is projected to reach a revised size of US$ 8137 million by 2031, growing at a CAGR of 7.8% during the forecast period.
Published: 2025-01-16
Pages: 80
USD 2900.00 (Single User License)Global Varicella Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-16
Pages: 130
USD 5900.00 (Single User License)Global Varicella Vaccine Market Insights, Forecast to 2030
Varicella vaccine, also known as chickenpox vaccine, is a vaccine that protects against chickenpox. One dose of vaccine prevents 95% of moderate disease and 100% of severe disease. Two doses of vaccine is more effective than one. If given to those who are not immune within five days of exposure to chickenpox it prevents most cases of disease. Vaccinating a large portion of the population also protects those who are not vaccinated. It is given by injection just under the skin
Published: 2024-04-07
Pages: 87
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 5600.00
USD 8400.00
USD 11200.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now